BIOMAT Database Logo BIOMAT Database Logo

One-year study of fluphenazine enanthate. 1967

J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010640 Phenothiazines Compounds containing dibenzo-1,4-thiazine. Some of them are neuroactive.
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D005116 Extrapyramidal Tracts Uncrossed tracts of motor nerves from the brain to the anterior horns of the spinal cord, involved in reflexes, locomotion, complex movements, and postural control. Extrapyramidal Tract,Tract, Extrapyramidal
D005260 Female Females
D005476 Fluphenazine A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. Flufenazin,Fluphenazine Hydrochloride,Lyogen,Prolixin,Hydrochloride, Fluphenazine

Related Publications

J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
[Fluphenazine enanthate].
September 1966, Revista brasileira de medicina,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
A DOUBLE BLIND STUDY OF FLUPHENAZINE ENANTHATE.
August 1965, Diseases of the nervous system,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Fluphenazine enanthate induced decompensations.
January 1975, Psychosomatics,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Fluphenazine enanthate in schizophrenia.
August 1970, British medical journal,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Fluphenazine enanthate and schizophrenia.
January 1969, British medical journal,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Large doses of fluphenazine enanthate.
April 1972, British medical journal,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Large doses of fluphenazine enanthate.
July 1972, British medical journal,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Fluphenazine enanthate and fluphenazine decanoate: a comparative study in chronic schizophrenic outpatients.
January 1969, Psychosomatics,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
Hospital experience with fluphenazine enanthate.
October 1970, Diseases of the nervous system,
J J Hsu, and E Nol, and M L Martinez, and B Lessien, and P G Paragas, and M Puhac, and R A Braun
A clinical evaluation of fluphenazine enanthate.
September 1970, Diseases of the nervous system,
Copied contents to your clipboard!